Antiangiogenic Therapy for von Hippel-Lindau Disease [4]

JAMA

Volumn 291, Issue 8, 2004, Pages 943-944

  Madhusudan, Srinivasan ^a   Deplanque, Gael ^a,f   Braybrooke, Jeremy P ^a   Cattell, Emma ^a   Taylor, Marian ^a   Price, Pat ^b   Tsaloumas, Marie D ^c   Moore, Niall ^d   Huson, Susan M ^d   Adams, Chris ^d   Frith, Peggy ^d   Scigalla, Paul ^e   Harris, Adrian L ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e SUGEN INC   (United States)

^f Clinique Claude Bernard   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CHLORPHENIRAMINE; DEXAMETHASONE; RANITIDINE; SEMAXANIB; VASCULOTROPIN; VASCULOTROPIN C; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ARTHRALGIA; CLINICAL ARTICLE; DIARRHEA; DRUG WITHDRAWAL; FAMILIAL CANCER; FATIGUE; GENE MUTATION; HEADACHE; HEMANGIOBLASTOMA; HUMAN; LETTER; NAUSEA; PRIORITY JOURNAL; PRURITUS; TUMOR SUPPRESSOR GENE; VISUAL ACUITY; VOMITING; VON HIPPEL LINDAU DISEASE; BLOOD; BRAIN TUMOR; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RETINA TUMOR; SPINAL CORD TUMOR; TREATMENT OUTCOME;

ADULT; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; FEMALE; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; INDOLES; MALE; MIDDLE AGED; PYRROLES; RETINAL NEOPLASMS; SPINAL CORD NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 10744224667     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.8.943     Document Type: Letter

References (9)

1. Friedrich CA. von Hippel-Lindau syndrome: a pleomorphic condition. Cancer. 1999;86(suppl 11):2478-2482.
2. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673-682.
3. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 1995;55:1358-1364.
4. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
5. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res. 2002;8:2798-2805.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
7. National Cancer Institute. Common Toxicity Criteria. Available at: http://ctep .info.nih.gov/reporting/CTC-3.html. Accessibility verified January 27, 2004.
8. Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology. 2002;109:1745-1751.
9. Girmens JF, Erginay A, Massin P, Scigalla P, Gaudric A, Richard S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangloblastomas. Am J Ophthalmol. 2003;136:194-196.